`Danford Declaration
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________________________________________
`
`CELLTRION, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________________________________________
`
`Case IPR2017-01373
`U.S. Patent 6,407,213
`____________________________________________
`
`DECLARATION OF ANDREW J. DANFORD IN SUPPORT OF
`MOTION FOR ADMISSION PRO HAC VICE
`
`
`
`
`
`
`
`
`
`
`
`
`
`Genentech 2036
`Celltrion v. Genentech
`IPR2017-01373
`
`
`
`
`
`
`I, Andrew J. Danford, declare as follows:
`
`Case No. IPR2017-01373
`Danford Declaration
`
`1.
`
`I was admitted to the Massachusetts Bar in January of 2009 and the New
`
`York Bar in August of 2010 and have been practicing law for over 7 years.
`
`During the entire time that I have been practicing law, my practice has
`
`focused on the field of intellectual property, and particularly, patent
`
`litigation.
`
`2.
`
`I am a member in good standing of the Massachusetts and New York Bars,
`
`and am admitted to practice before the United States District Court for the
`
`District of Massachusetts, the United States Court of Appeals for the First
`
`Circuit, and the United States Court of Appeals for the Federal Circuit.
`
`3. My New York Bar membership number is 4855318. My Massachusetts Bar
`
`membership number is 672342.
`
`4.
`
`Over the course of my career, I have been counsel in numerous patent
`
`litigations. Several of these cases have concerned Patent Office rules and
`
`regulations. For example, I represented Cephalon, Inc. in Apotex Inc. v.
`
`Cephalon, Inc., No. 12-1417 (Fed. Cir.).
`
`5.
`
`I have never been suspended or disbarred from practice before any court or
`
`administrative body.
`
`
`
`
`1
`
`
`
`
`
`
`6.
`
`Case No. IPR2017-01373
`Danford Declaration
`
`I have never had a court or administrative body deny my application for
`
`admission to practice.
`
`7.
`
`I have never had any sanctions or contempt citations imposed on me by any
`
`court or administrative body.
`
`8.
`
`I have read and will comply with Office Patent Trial Practice Guide and the
`
`Board’s Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.
`
`9.
`
`I agree to be subject to the United States Patent and Trademark Office Rules
`
`of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`10.
`
`I represent Patent Owner Genentech, Inc. in a number of pending IPR
`
`proceedings, including IPR2017-00731 (institution denied July 27, 2017,
`
`request for rehearing filed August 25, 2017; pro hac vice granted October 2,
`
`2017; instituted October 26, 2017, pending); IPR2017-00737 (pro hac vice
`
`granted June 21, 2017, pending); IPR2017-00739 (pro hac vice granted June
`
`21, 2017; institution denied July 27, 2017); IPR2017-00804 (pro hac vice
`
`granted October 2, 2017, pending); IPR2017-00805 (pro hac vice granted
`
`October 2, 2017, pending); IPR2017-01121 (pro hac vice granted, October
`
`30, 2017, pending); IPR2017-01122 (pro hac vice granted, October 30,
`
`2017, pending); IPR2017-01139 (pro hac vice granted October 30, 2017,
`
`pending); IPR2017-01140 (pro hac vice motion granted October 30, 2017,
`
`
`
`
`2
`
`
`
`
`
`Case No. IPR2017-01373
`Danford Declaration
`
`pending); IPR2017-01374 (pro hac vice motion to be filed, pending);
`
`IPR2017-01488 (pro hac vice granted September 27, 2017, pending);
`
`IPR2017-01489 (pro hac vice granted September 27, 2017, pending);
`
`IPR2017-01726 (pro hac vice motion to be filed, pending); IPR2017-01727
`
`(pro hac vice motion to be filed, pending); IPR2017-01958 (pro hac vice
`
`motion to be filed; pending); IPR2017-01959 (pro hac vice motion to be
`
`filed, pending); IPR2017-01960 (joined to IPR2017-00737); IPR2017-02031
`
`(pro hac vice to be filed, pending); IPR2017-02032 (pro hac vice to be filed,
`
`pending); IPR2017-02063 (pro hac vice to be filed, pending); IPR2017-
`
`02139 (pro hac vice to be filed, pending); IPR2017-02140 (pro hac vice to
`
`be filed, pending); IPR2018-00016 (pro hac vice to be filed, pending);
`
`IPR2018-00192 (pro hac vice to be filed, pending). I have also assisted
`
`Patent Owner Genentech, Inc. in a number of IPR proceedings, including
`
`IPR2015-01624, which was terminated due to settlement; IPR2016-00710,
`
`which was terminated due to settlement; IPR2016-01373, which was not
`
`instituted; IPR2016-00460, which was joined with IPR2015-01624 (which
`
`was terminated due to settlement); IPR2016-00383, which was not
`
`instituted; and IPR2017-00047, which was joined with IPR2016-00710
`
`(which was terminated due to settlement). I also assisted Patent Owner
`
`Genentech, Inc. in IPR2016-01693 (challenging U.S. Patent No. 6,407,213,
`
`3
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2017-01373
`Danford Declaration
`
`that patent at issue in this case) and IPR2016-01694 (challenging U.S. Patent
`
`No. 6,407,213, that patent at issue in this case), which were terminated due
`
`to settlement.
`
`11.
`
`I am intimately familiar with the subject matter of U.S. Patent No. 6,407,213
`
`and the prior art at issue in this proceeding. I am also intimately familiar
`
`with antibody technology as a result of my participation in prior antibody-
`
`related patent cases such as IPR2015-01624. I have also represented
`
`Genentech in prior challenges (IPR2016-01693 and IPR2016-01694) to U.S.
`
`Patent No. 6,407,213, the patent at issue in this case. In addition, I have
`
`represented life sciences and pharmaceutical companies, including AbbVie,
`
`Bristol-Myers Squibb, Takeda Pharmaceuticals, AstraZeneca, and Cephalon
`
`in patent litigation matters before federal district courts and the Federal
`
`Circuit. The technology involved in these disputes includes drugs for a
`
`variety of disease conditions, including hyperlipidemia, HIV, hepatitis B,
`
`pulmonary diseases, and sleep disorders.
`
`12.
`
`I hereby declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to
`
`be true; and further that these statements are made with the knowledge that
`
`willful false statements and the like are punishable by fine, imprisonment, or
`
`both, under Section 1001 of Title 18 of the United States Code.
`
`
`
`
`4
`
`
`
`
`
`
`
`
`
`
`Dated: January 3, 2018
`
`Case No. IPR2017-01373
`Danford Declaration
`
`
`Respectfully submitted,
`
`
`
`
`/Andrew J. Danford/
`Andrew J. Danford
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`60 State Street
`Boston, Massachusetts 02109
`andrew.danford@wilmerhale.com
`Tel.: 617-526-6806
`Fax: 617-526-5000
`
`
`
`
`5
`
`
`
`